

Product Sheet

H_IL33 Reporter 293 Cell Line


Catalog number: GM-C12812

Version 3.3.1.241129

IL-33 (Interleukin-33) is a cytokine belonging to the IL-1 family, and it is an important inflammatory mediator. IL-33 is mainly expressed in various cells, especially in epithelial cells, endothelial cells, and certain immune cells.

IL-33 interacts with the receptor ST2 (also known as IL1RL1) and the IL-1 receptor accessory protein (IL1RAP). The IL-33 receptor is expressed in T cells (particularly Th2-like cells), macrophages, basophils, and NK cells. IL-33 plays a crucial role in amplifying mucosal and systemic immune responses, providing therapeutic opportunities for conditions such as asthma and autoimmune diseases.

H_IL33 Reporter 293 Cell Line is a clonal stable 293 cell line constructed using lentiviral technology, constitutive expression of the IL1RL1, IL1RAP, along with signal-dependent expression of a luciferase reporter gene. The addition of IL33 ligand protein agonists stimulates IL33 to bind IL1RL1, IL1RAP, activating downstream reporter genes and inducing luciferase expression. This system can be used to evaluate the in vitro effects of drugs related to IL33.



Specifications

Quantity	5E6 Cells per vial, 1 mL
Product Format	1 vial of frozen cells
Shipping	Shipped on dry ice
Storage Conditions	Liquid nitrogen immediately upon receipt
Recovery Medium	EMEM(ATCC)+10% FBS+1% P.S
Growth medium	EMEM(ATCC)+10% FBS+1% P.S+3 µg/mL Blasticidin+400 µg/mL G418+1.5 µg/mL Puromycin
Note	Cells should be cultured using ATCC/30-2003 EMEM medium or complete culture medium from Genomeditech. The serum should be Cegrogen biotech/A0500-3010 or Gibco serum.
Freezing Medium	90% FBS+10% DMSO
Growth properties	Adherent
Growth Conditions	37°C, 5% CO ₂
Mycoplasma Testing	The cell line has been screened to confirm the absence of Mycoplasma species.
Safety considerations	Biosafety Level 2
Note	It is recommended to expand the cell culture and store a minimum of 10 vials at an early passage for potential future use.

Materials

Reagent	Manufacturer/Catalogue No.
EMEM	ATCC/30-2003
Fetal Bovine Serum	Cegrogen biotech/A0500-3010
Pen/Strep	Thermo/15140-122
Blasticidin	Genomeditech/ GM-040404
G418	Genomeditech/ GM-040402
Puromycin	Genomeditech/ GM-040401
Recombinant Human IL-33 Protein	R&D SYSTEMS/3625-IL
Anti-IL33 hIgG4 Antibody(Itepekimab)	Genomeditech/ GM-31628AB
GMOne-Step Luciferase Reporter Gene Assay Kit	Genomeditech/ GM-040503

Figures




Figure 1 | Response to Human IL33 ligand protein. H_IL33 Reporter 293 Cell Line (Cat. GM-C12812) at a concentration of 1.3E4 cells/well (96-well format) was stimulated with serial dilutions of Human IL-33 Protein (R&D/3625-IL-010) in assay buffer (EMEM+1% FBS+1% P.S) for 16 hours. The firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The maximum induction fold was approximately [31]. Data are shown by drug mass concentration.




Figure 2 | Response to Human IL33 ligand protein. H_IL33 Reporter 293 Cell Line (Cat. GM-C12812) at a concentration of 1.3E4 cells/well (96-well format) was stimulated with serial dilutions of Human IL-33 Protein (R&D/3625-IL-010) in assay buffer (EMEM+1% FBS+1% P.S) for 16 hours. The firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The maximum induction fold was approximately [31]. Data are shown by drug molar concentration.




Figure 3 | Response to Anti-IL33 hIgG4 Antibody (Itepekimab). Begin by preparing the H_IL33 Reporter 293 Cell Line (Cat. GM-C12812) at a density of 2E4 cells/well in a 96-well format. The serial dilutions of Anti-IL33 hIgG4 Antibody (Itepekimab) (Cat. [GM-31628AB](#)) were incubated with 30 ng/mL of Human IL33 (R&D/3625-IL-010) for 1 hour. After pre-incubation, the mixture was added to the H_IL33 Reporter 293 Cell Line and incubated for 16 hours in assay buffer (EMEM + 1% FBS + 1% P.S). Firefly luciferase activity is then measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. [GM-040503](#)). The results indicated a maximum blocking fold of approximately [3.9], with data represented by drug mass concentration.




Figure 4 | Response to Anti-IL33 hIgG4 Antibody (Itepekimab). Begin by preparing the H_IL33 Reporter 293 Cell Line (Cat. GM-C12812) at a density of 2E4 cells/well in a 96-well format. The serial dilutions of Anti-IL33 hIgG4 Antibody (Itepekimab) (Cat. [GM-31628AB](#)) were incubated with 30 ng/mL of Human IL33 (R&D/3625-IL-010) for 1 hour. After pre-incubation, the mixture was added to the H_IL33 Reporter 293 Cell Line and incubated for 16 hours in assay buffer (EMEM + 1% FBS + 1% P.S). Firefly luciferase activity is then measured using the GMOne-Step

Luciferase Reporter Gene Assay Kit (Cat. [GM-040503](#)). The results indicated a maximum blocking fold of approximately [3.9], with data represented by drug molar concentration.




Figure 5 | The passage stability of response to Human IL-33 ligand protein. The passage 4 and 14 of H_IL33 Reporter 293 Cell Line (Cat. GM-C12812) at a concentration of 1.5E4 cells/well (96-well format) was stimulated with serial dilutions of Human IL-33 Protein (R&D/3625-IL-010) in assay buffer (EMEM+1% FBS+1% P.S) for 16 hours. The firefly luciferase activity was measured using the GOne-Step Luciferase Reporter Gene Assay Kit (Cat. [GM-040503](#)). Data are shown by drug mass concentration.

Cell Recovery

Recovery Medium: EMEM(ATCC)+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

- a) Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).
- b) Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
- c) Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.
- d) Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.
- e) Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

- a) Centrifuge at 176 x g for 3 minutes to collect cells.
- b) Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.
- c) Aliquot 1 mL into each vial.
- d) Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: EMEM(ATCC)+10% FBS+1% P.S+3 µg/mL Blasticidin+400 µg/mL G418+1.5 µg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

- a) Remove and discard culture medium.
- b) Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.
- c) Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 30 to 60 seconds at 37°C).
- d) Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- e) Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.
- f) After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.
- g) Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:3 - 1:4 is recommended

Medium Renewal: Every 2 to 3 days

Notes

- a) Upon initial revival, a higher number of dead cells and poor adherence are observed, which is normal. Adherence typically recovers within 2 - 3 days. After 2 - 3 passages, the proportion of adherent cells increases, and the cells begin to spread normally.
- b) After each passage, there may be 5 - 10% dead cells; however, as the number of passages increases, the recovery rate accelerates, the proportion of dead cells decreases, and the cell growth rate stabilizes.
- c) It is recommended to retain cell images after revival and during each observation to assist in assessing cell status. In case of abnormalities, promptly communicate with Genomeditech sales.

Related Products

IL-33	
Anti-IL33 hIgG4 Antibody(Itepekimab)	Anti-IL33 hIgG4 Reference Antibody (Itepbio)

Limited Use License Agreement

Genomeditech (Shanghai) Co., Ltd grants to the Licensee all intellectual property rights, exclusive, non-transferable, and non-sublicensable rights of the Licensed Materials; Genomeditech (Shanghai) Co., Ltd will retain ownership of the Licensed Materials, cell line history packages, progeny, and the Licensed Materials including modified materials.

Between Genomeditech (Shanghai) Co., Ltd, and Licensee, Licensee is not permitted to modify cell lines in any way. The Licensee shall not share, distribute, sell, sublicense, or otherwise provide the Licensed Materials, or progenitors to third parties such as laboratories, departments, research institutions, hospitals, universities, or biotechnology companies for use other than for the purpose of outsourcing the Licensee's research.

Please refer to the Genomeditech Cell Line License Agreement for details.

Genomeditech